ArticlePloS one2025
Computational prediction of high-risk non-synonymous SNPs in human ApoE and their structural impact on amyloid-β interaction in Alzheimer's disease pathogenesis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Prevalence and antibiotic resistance pattern of Staphylococcus spp. isolated from acne, and disrupting their antimicrobial resistance: unveiling the potential of Ganoderma lucidum extract.Journal, genetic engineering & biotechnology · 2026Article
- Computational identification and characterization of high-risk human KRAS nsSNPs: Impacting structure, ligand binding, and cancer prognosis.Journal, genetic engineering & biotechnology · 2026Article
- Exploring the neuroprotective, antioxidant, and anti-amyloid effects of Ganoderma lucidum compounds in Alzheimer's disease: insights from experimental and computational approaches.Journal, genetic engineering & biotechnology · 2026Article
- Biochemical characterization of aspartylglucosaminidase missense variants of unclear significance reveals different degrees of functional impairment.Frontiers in chemistry · 2026Article
- Novel Pyrazoline Derivatives as Therapeutic Candidate for Alzheimer's Disease: An Integrated Network Pharmacology and 3D-QSAR Modelling.Bioinformatics and biology insights · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apolipoprotein E (ApoE) plays a critical role in Alzheimer's disease (AD) by regulating amyloid beta (Aβ) clearance through direct interaction. Non-synonymous single nucleotide polymorphisms (nsSNPs) in ApoE alter its structure and impair function, contributing to disease progression. This study aimed to identify functionally damaging nsSNPs in the ApoE gene using in silico tools and to assess their structural and binding effects on Aβ in the context of AD progression. A total of 376 nsSNPs were retrieved from dbSNP, ClinVar, and DisGeNET databases. Eight predictive tools (SIFT, PolyPhen-2, PredictSNP, PhD-SNP, PANTHER, PROVEAN, Meta-SNP, and SNAP2) were employed to identify deleterious variants. Protein stability was assessed using I-Mutant 2.0, MUpro, INPS-MD, iStable, and DynaMut2, while structural effects were evaluated via HOPE, MutPred2, Swiss-PDB Viewer, and Missense3D. Domain localization was determined using InterPro. Molecular docking was performed using PyRx and AutoDock Vina. Molecular dynamic simulation (MDS) evaluate binding stability and dynamics through 100-ns by Schrödinger Maestro, analyzing RMSD, RMSF, Rg, SASA. Out of 376 nsSNPs, 10 were consistently predicted as deleterious by all eight computational tools. Among these, two variants (L107P and L122P) were classified as high-risk and located within the receptor-binding domain of ApoE. The receptor-binding domain mediates the interaction between ApoE and Aβ. Molecular docking revealed binding affinities of -5.5 kcal/mol (WT), -5.6 kcal/mol (L107P), and -6.6 kcal/mol (L122P), indicating stronger Aβ binding by L122P. Stronger binding affinity of L122P mutation may promote Aβ aggregation or hinder clearance, potentially contributing to disease severity. MDS showed L122P had the highest structural stability, with the lowest RMSD, RMSF, Rg values and increased SASA, supporting its enhanced interaction with Aβ. These findings suggest that L122P mutation may enhance Aβ aggregation or hinder its clearance, potentially worsening AD and highlight the structural and functional impact of ApoE variants and the need for experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.